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Aberrant promoter DNA hypermethylation is a hallmark of cancer; however, whether this is
sufﬁcient to drive cellular transformation is not clear. To investigate this question, we use a
CRISPR-dCas9 epigenetic editing tool, where an inactive form of Cas9 is fused to DNA
methyltransferase effectors. Using this system, here we show simultaneous de novo DNA
methylation of genes commonly methylated in cancer, CDKN2A, RASSF1, HIC1 and PTEN in
primary breast cells isolated from healthy human breast tissue. We ﬁnd that promoter
methylation is maintained in this system, even in the absence of the fusion construct, and this
prevents cells from engaging senescence arrest. Our data show that the key driver of
this phenotype is repression of CDKN2A transcript p16 where myoepithelial cells harbour
cancer-like gene expression but do not exhibit anchorage-independent growth. This work
demonstrates that hit-and-run epigenetic events can prevent senescence entry, which may
facilitate tumour initiation.
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The epigenomic landscape is signiﬁcantly perturbed duringcancer development. In the case of DNA methylation, thebest characterised epigenetic modiﬁcation to date, the
pattern of aberrant modiﬁcations is similar across different can-
cers1. In general, cancer cells have a hypomethylated genome,
with some promoter CpG islands (CGIs) becoming
hypermethylated2–5 and the mechanism of this process is largely
unknown. Since more than half of the coding genes contain a
promoter CGI, which when methylated can inhibit their gene
expression, hypermethylation can frequently result in tumour
suppressor gene inactivation6. Previously, it has been difﬁcult to
dissociate passenger aberrant epigenetic changes from drivers in
cancer initiation due to the lack of suitable experimental tools7, 8.
Recent advances in epigenome editing are now enabling us to
identify the role of DNA methylation in early tumorigenesis. The
catalytic domain of de novo methyltransferase DNMT3A (in
combination with DNMT3L in some studies) has been coupled to
zinc ﬁnger proteins9–12, TALEs (transcription activator-like
effectors)13, and most recently the catalytically inactive dCas9-
CRISPR (clustered regularly interspaced short palindromic
repeats) system14–17, to introduce DNA methylation to a target
locus. These studies have shown that DNA methylation can be
successfully targeted, dependent on the combination of effector
domains and localised chromatin conﬁrmation, and that this has
a direct effect on cell biology.
Successful DNA methylation editing using CRISPR has been
shown in multiple cell lines14–16, 18, primary T cells16 and most
recently in the mouse brain18, although the maintenance of
methylation is often limited without constitutive expression of the
Cas9 construct14, 15, 19. Using CRISPR to co-target three effector
domains, DNMT3A, DNMT3L and KRAB resulted in permanent
hypermethylation after transient transfection in cell lines16,
whereas targeting only DNMT3A and KRAB did not, high-
lighting the importance of the local chromatin microenvironment
in the effectiveness of these tools. Targeting DNA methylation
with CRISPR has an interesting spreading effect as demonstrated
recently, where a single gRNA resulted in DNA hypermethylation
across the CGI17. These pioneering studies show the versatility
and enormous potential for utilising CRISPR for epigenomic
editing and have paved the way for our work interrogating the
direct effect of DNA methylation on biological processes.
Here we transiently transfect dCas9 DNMT3A-3L (dCas9
3A3L) and show that DNA methylation can be targeted to
multiple genes in primary breast cells isolated from healthy
human tissue, resulting in long term hypermethylation and gene
silencing. Cells are prevented from entering senescence and
hyper-proliferate, a phenotype driven by p16 repression. Edited
myoepithelial cells harbour cancer-like gene expression changes
but are not immortal, indicating activation of early abnormal
cellular processes which may enable cells to move towards
transformation.
Results
Hypermethylation of tumour suppressors in primary cells. To
investigate whether promoter DNA hypermethylation can drive
cellular transformation we established DNA methylation target-
ing in normal primary human myoepithelial cells isolated from
healthy donors. The cell of origin in breast cancer is controversial
but mammary stem cells may reside in the myoepithelial niche,
contributing to both myoepithelial and luminal cell
populations20, 21. We ﬁrst optimised the transfection protocol in a
myoepithelial cell line, 1089, cells which were isolated from
healthy breast tissue and then immortalised22, 23. The dCas9
3A3L fusion plasmid contains the catalytic domain of mouse
Dnmt3a and C-terminal domain of Dnmt3l (3A3L) coupled to a
catalytically dead Cas917. Cells were transiently transfected with
the constructs and 5 days later analysed for DNA methylation
changes (Supplementary Fig. 1a). Five guide RNAs (gRNAs)
targeting the CGI overlapping the HIC1 gene promoter were
designed to ensure DNA methylation spreading14, 15 (Supple-
mentary Fig. 1b) and this region was normally hypomethylated in
parental 1089 cells (Supplementary Fig. 1b). dCas9 3A3L or the
control 3A3LΔ (Supplementary Fig. 1c, 3A3LΔ construct inactive
for methyltransferase function) were co-transfected with the
gRNAs and DNA methylation was successfully targeted to the
HIC1 promoter in 1089 cells (Supplementary Fig. 1d).
Transiently targeting DNA methylation can result in a spike of
hypermethylation within 6–10 days before a rapid decline14, 16, 19.
We checked this in 1089 cells and found HIC1 promoter
hypermethylation at 5 days post-transfection when 25% of cells
remained dCas9-positive (dCas9+ve; Supplementary Fig. 1e). By
day 10 post-transfection DNA methylation was maintained
although less than 1% of these cells were dCas9+ve, indicating
that methylation had persisted in the absence of the fusion
construct. However, at 15 days post transfection HIC1 was once
again hypomethylated (Supplementary Fig. 1e). Our results
validated previous ﬁndings that DNA methylation can be
successfully targeted in cell lines; that in 1089 cells the
modiﬁcation was propagated for a few cell divisions but was lost
in the absence of the effector fusion protein17.
Unlike 1089 cells, primary myoepithelial cells go through a
ﬁnite number of cell divisions before entering senescence (likely
to be p16-induced based on work in primary breast cells24) and
are challenging to transfect. We therefore allowed the primary
cells to proliferate for 3 days before transfection (Fig. 1a). We
designed ﬁve gRNAs to the HIC1 and RASSF1A promoters
(Fig. 1b, c) and at 5 days post-transfection we identiﬁed DNA
hypermethylation at both HIC1 and RASSF1A promoters when
targeting dCas9 3A3L compared to dCas9 3A3LΔ (Fig. 1b, c;
lower panels), indicating that transient transfection could be used
to successfully target multiple genes in primary cells.
Off-target DNA methylation effects of dCas9 3A3L targeting.
After demonstrating that we could successfully hypermethylate
promoter CGIs in primary cells, we selected a panel of genes with
substantial evidence suggesting a role in cellular transformation
in breast cancer. Previous studies have identiﬁed DNA promoter
hypermethylation at CDKN2A25–28, PTEN29–31, HIC132 and
particularly RASSF13, 25, 26, 29, 33, 34 genes in early and late stage
breast cancer. Furthermore, data mining35 from 743 invasive
breast carcinomas available from The Cancer Genome Atlas
(TCGA) showed these genes become hypermethylated in some
tumours (Supplementary Fig. 2). We limited our panel to four
genes as this required transfection of 26 plasmids to cover the
CGIs. Separately, we conﬁrmed using 1089 cells that lipophilic
based transfections resulted in the presence of dCas9 3A3L and
pMACS (for magnetic sorting) proteins in the same cells (Sup-
plementary Fig. 2e). We were therefore conﬁdent that most
transfected cells contained all the constructs. In addition to HIC1
(Fig. 1b and Fig. 2a) and RASSF1A (Figs. 1c and 2c) we designed
gRNAs against the CGI at the PTEN gene promoter (Fig. 2b); the
CGI at RASSF1B and RASSF1C transcriptional start sites (TSS)
(Fig. 2c); two CGIs overlapping CDKN2A at the TSS for
p16INK4a (p16) and p14ARF (p14) transcripts; and a third par-
tially hypomethylated downstream CGI (Fig. 2d). Gene expres-
sion analysis showed low levels of HIC1, RASSF1A and p14,
compared to higher total RASSF1, PTEN and p16 expression in
early passage cells (Supplementary Fig. 3a). We co-transfected all
gRNAs and conﬁrmed successful DNA methylation targeting at
the HIC1 gene promoter after 5 days (Supplementary Fig. 3b). At
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10 days post-transfection we analysed DNA methylation using
the Inﬁnium HumanMethylationEPIC (EPIC) array. Figure 2a–e
show successful and signiﬁcant hypermethylation of the target
CGIs. Consistent with the cell line data and previous reports, we
observed DNA methylation spreading from the site of the gRNA
binding (e.g. upstream to the PTEN gRNA #1 in Fig. 2b). EPIC
array probes associated with the target genes that had a signiﬁcant
and more than 20% methylation increase in dCas9 3A3L com-
pared to the control dCas9 3A3LΔ cells are highlighted in Fig. 2e.
The scatter plot shows a high correlation (R= 0.99) between the
targeted and control cells, indicating little epigenome rearrange-
ment at this stage (Fig. 2e).
Notably, we found 946 other CpGs that were consistently
≥ 20% hypermethylated in the dCas9 3A3L vs. dCas9 3A3LΔ
transfected cells (0.1% of total CpGs measured), and only 185
CpGs were hypomethylated (Supplementary Data 1). The
hypermethylated probes were signiﬁcantly enriched in CGIs,
CGI shores, and exons (above expected vs. all the EPIC probes)
indicating a preference for hypermethylation at these genomic
features (Fig. 2f). Out of all 946 off-targets only two genes
contained more than 3 hypermethylated probes within 1–2
kilobases: the promoter of G0S2 and the gene body of C10orf41/
ZNF503-AS2 (Supplementary Fig. 4a, b). Hypermethylation
events, other than our targets, may be genuine off-targets
(some gRNA dependent or independent) or a consequence of
the biological effect caused by on-target hypermethylation (as it
has been previously reported for G0S2 hypermethylation36).
Identifying the extent of off-target effects associated with dCas9
based epigenetic editing is an important area for future work.
We checked whether DNA methylation targeting had sup-
pressed HIC1, RASSF1, PTEN and CDKN2A associated gene
expression at day 10 post-transfection using RNA-sequencing
(RNA-seq) and targeted qPCR (Fig. 2g, h). p16 expression
increased signiﬁcantly in 3A3LΔ control cells, indicating that
primary myoepithelial cells indeed go into p16-induced senes-
cence in culture. This expression was strongly suppressed in the
3A3L targeted cells (Fig. 2g). We found that p14 was also
downregulated in the 3A3L targeted cells. RASSF1A was repressed
in both 3A3L and 3A3LΔ targeted cells compared to early passage
(indicating downregulation in senescence, see Discussion), with a
stronger repression in 3A3L targeted cells. The expression of
other RASSF1 transcripts was also signiﬁcantly downregulated in
3A3L targeted cells compared to 3A3LΔ. HIC1 and PTEN
expression were similar between 3A3L targeted cells compared to
3A3LΔ. Taken together, the data suggest that transiently targeting
dCas9 3A3L resulted in DNA methylation deposition to all 4
targeted genes, but only expression of CDKN2A and RASSF1 were
signiﬁcantly reduced at 10 days post-transfection.
Increased proliferation of dCas9 3A3L targeted cells. We
assessed whether our treatment had affected primary myoe-
pithelial cell biology. Since a key hallmark of abnormality in
cancer is uncontrolled cellular replication we quantitatively
measured proliferation using a colorimetric based assay. We
found that DNA methylation targeting resulted in rapid pro-
liferation of cells after 15 days (Fig. 3a); the result was similar
when using myoepithelial cells from two additional healthy
donors (Fig. 3b). To compare the rate of population growth in
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Fig. 1 dCas9 3A3L targeted hypermethylation of HIC1 and RASSF1 in primary myoepithelial cells. a Schematic of experimental design, 10 plasmids encoding
gRNAs targeting HIC1 and RASSF1A promoters were transfected along with dCas9 3A3L or 3A3LΔ and the MACS (magnetic activated cell sorting) plasmid
(pMACS) for magnetic selection. b A schematic depicting the gRNA location (grey arrows) in relation to the CGI (in green) and the TSS in the promoter of
the HIC1 gene; the arrows point towards the PAM sequence. The dotted lines represent the region analysed by bisulﬁte cloning and the locations of
individual CpGs are scaled according to their genomic distribution. The dark blue shading depicts which CpGs are overlapped by gRNA #5. Lower panel
shows bisulﬁte cloning results from the HIC1 locus 5 days after transfecting primary myoepithelial cells from donor 1 with 10 gRNAs (targeting HIC1 and
RASSF1) and dCas9 3A3L or 3A3LΔ as indicated. c A schematic depicting gRNA in relation to CGI and TSS in the promoter of RASSF1A. Lower panel shows
bisulﬁte cloning from RASSF1A 5 days after transfection of primary human myoepithelial cells with 10 gRNAs (targeting HIC1 and RASSF1) and dCas9 3A3L
or 3A3LΔ as indicated. Arrows and green shading represent overlap between gRNAs and CpGs. Each line represents a single clone, ﬁlled and empty
lollipops represent a single methylated or unmethylated CpG, respectively
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3A3L targeted cells compared to controls we measured popula-
tion doublings (Fig. 3c). The growth of 3A3LΔ and untransfected
cells slowed by 15 days post-transfection when cells start to
senesce, staining positive for beta-galactosidase (β-gal; Fig. 3d)
while cells targeted with dCas9 3A3L continue to proliferate for at
least 35 days (up to 80 days). Regarding cell morphology, the
3A3L targeted cells are smaller and similar to that of early passage
cells (Supplementary Fig. 5a, b) whereas the 3A3LΔ and
untransfected cells become large and ﬂat, typical of senescent cells
(Fig. 3d). We observed a seeding density effect on this pro-
liferative phenotype, with cells initially seeded at low density (780
cells cm−1± 10%) proliferating signiﬁcantly more than at high
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density (3120 cells cm−1 ± 10%) after 15 to 20 days post-
transfection (Supplementary Fig. 6a). We used the IncuCyte
ZOOM™ live-cell imaging platform (Supplementary Movies 1 and
2) to track cell growth from 10 days post-transfection. This
revealed that cells seeded at high density rapidly migrated toge-
ther forming small clusters and did not proliferate (Supplemen-
tary Fig. 6b, c). The low density cells proliferated exponentially
before reaching a plateau (Supplementary Fig. 6c, d). We spec-
ulate that the proliferation inhibition of myoepithelial cells seeded
at high density is induced by paracrine signalling.
We performed additional experiments to test the contribution
of unspeciﬁc effects to the proliferative phenotype. For these
experiments (Figs. 3e and 6) we performed the transfections
without pMACS magnetic enrichment to reduce cell loss and
maximise the number of transfection conditions possible per
experiment. Primary cells transfected with dCas9 3A3L without
gRNAs did not proliferate, conﬁrming that gRNA-independent
binding of dCas9 3A3L does not prevent senescence (Fig. 3e). We
targeted the panel of genes with a dCas9 3A3L catalytic mutant,
where the C706A substitution inactivates the methyltransferase
function and the targeted cells did not start proliferating (Fig. 3e;
Supplementary Fig. 7). Finally, we used dCas9 without the 3A3L
fusion construct and the 26 gRNAs and similarly saw no
proliferation, excluding a dCas9-interference effect on gene
expression (Fig. 3e). Interestingly, using dCas9 3A did result in
senescence prevention indicating that DNMT3A targeting is
sufﬁcient in our system to drive the proliferative phenotype17. In
summary, primary myoepithelial cells from three healthy donors
consistently evaded senescence and were highly proliferative after
DNA methylation targeting to the panel of tumour suppressor
genes.
Second cell stasis due to critically shortened telomeres. Pro-
longed culturing of DNA methylation targeted cells resulted in
reduced proliferation and cell cycle arrest after 60–80 days, with
signs of cell crisis including: increase in cellular size, cytoplasmic
vacuoles and multiple nuclei (Supplementary Fig. 8a). This
growth proﬁle is similar to a well described phenomena that
occurs in a rare population of p16-hypermethylated human
mammary derived epithelial cells (variant HMECs; vHMECs)
originally isolated from healthy donor tissue24, 37–43. vHMECs
arise spontaneously in culture; however, throughout our experi-
ments we did not observe any spontaneous senescence escape in
dCas9 3A3LΔ targeted or untransfected cells, even after main-
taining deeply senescent cells for 63 days (Supplementary
Fig. 8b). This may be due to genetic or epigenetic variations
between donors, or differences in cell isolation and culture con-
ditions. We found increased Ki-67+ve cells at 36 days post-
transfection, a reﬂection of the rapid proliferation at this time
point; but this was lost by 98 days, when cells are in permanent
cell cycle arrest (Supplementary Fig. 8c). We identiﬁed small
clusters of CK8+ve cells 36 days post-transfection in 3A3L tar-
geted cells, a marker normally associated with luminal cells, but
these cells did not become more abundant at later time points.
The outgrowing cells were permanently CK14+ve, suggesting that
cells remained myoepithelial in lineage.
To determine whether the outgrowing cells were transformed
we assessed anchorage-independent growth. Cells were seeded at
three time points: 2, 10 and 30 days post-transfection. In all cases
there was no colony formation after 14 days (Supplementary
Fig. 9a); however, 3A3L targeted cells that were rescued from the
assay resumed proliferation in 2D culture vessels (Supplementary
Fig. 9b), indicating that cells are dormant in 3D culture but retain
proliferative potential.
In vHMECs the ﬁnal cell cycle arrest is driven by critically
shortened telomeres and immortalisation has been achieved by
overexpressing hTERT37, 44. To assess whether this is the case in
our cells we stably integrated a construct overexpressing hTERT
with a green ﬂuorescent protein (GFP) marker into 3A3L targeted
cells from donor 1, and conﬁrmed hTERT expression along with
continued repression of p16 and p14, as well as for a separate
experiment (Supplementary Fig. 10a–c). Over serial passages we
found that overexpression of hTERT provided a growth
advantage to the cells indicated by an increasing percentage of
GFP+ve cells vs. control (Fig. 3f). The population doublings of
hTERT overexpressing cells also increased vs. controls (Supple-
mentary Fig. 10d). In summary, primary myoepithelial cells
which evaded senescence entered a second, permanent, cell cycle
arrest after several months which was independent of p16
expression and was alleviated by overexpressing hTERT.
Targeted DNA methylation is propagated in dCas9 3A3L cells.
Since senescence prevention was consistently seen in primary
myoepithelial cells we asked how permanent DNA methylation
changes were in cells from independent donors during the
exponential growth phase. We used the EPIC array to compare
global DNA methylation in early passage primary myoepithelial
cells from 2 donors and then at 37–38 days after DNA methy-
lation targeting to the four genes. The early passage cells showed a
similar DNA methylation proﬁle (Fig. 4a, correlation 0.98),
however by day 37–38 the DNA methylation proﬁles were more
variable (Fig. 4b, correlation 0.90), but showed maintenance of
methylation at RASSF1 and CDKN2A in both donors and less
consistently at HIC1 and PTEN. Clustering all EPIC array data
using principle component analysis (PCA) showed that the dCas9
3A3L and 3A3LΔ targeted cells clustered separately and that
late passage cells have greater variability in the global DNA
methylation pattern (Supplementary Fig. 11). We further vali-
dated the maintenance of DNA methylation after 37–40 days
post-transfection at the four genes using targeted bisulﬁte
Fig. 2 On- and off-target hypermethylation of tumour suppressor genes in primary cells. a–d EPIC array at targeted promoter regions of a HIC1, b PTEN,
c RASSF1 and d CDKN2A. gRNA (grey arrows point towards PAM sequence) in relation to CGI (in green) and TSS of genes, percentage methylation from
dCas9 3A3LΔ targeted cells (pink line) compared to 3A3L targeted cells (black line), 10 days post-transfection of primary myoepithelial cells from donor 1
and after magnetic sorting on day 2 (mean± SEM; n= 3; excluding error bar if smaller than plotted point). e Scatter plot of EPIC data comparing dCas9
3A3LΔ to dCas9 3A3L targeted cells 10 days post-transfection. Signiﬁcantly hypermethylated probes from HIC1, PTEN, RASSF1 and CDKN2A genes are
highlighted on the plot (≥ 20% increase; n= 3; Bumphunter; p< 0.01; Benjamini-Hochberg (BH) correction). f Overlap of the 946 EPIC array probes
signiﬁcantly hypermethylated in dCas9 3A3L targeted cells vs. 3A3LΔ (inner ring) compared to the percentage overlap of all probes in the EPIC array
(outer ring) with CGIs, CGI shelves, CGI shores or CpG intergenic (top doughnut) and exons, introns or intergenic regions (bottom doughnut). Signiﬁcant
differences were calculated using regioner in R. g, h Gene expression of g p16 and h other target genes in primary myoepithelial cells from donor 1, 10 days
after transfection with dCas9 3A3LΔ (purple) or dCas9 3A3L (orange). qPCR data is normalised to ACTB expression and shown as fold change compared
to average gene expression in early passage cells (dotted line; mean± SEM, n= 3; T-tests. *p< 0.01 dCas9 3A3L compared to 3A3LΔ; $p< 0.01 dCas9
3A3L or 3A3LΔ compared to early passage cells). RNA-seq data is shown as fold change of target gene transcripts from 3A3L or 3A3LΔ compared to
average RPKM from early passage cells (dotted line; mean± SEM, n= 3). Signiﬁcance is from DESeq2 analysis with BH correction: *p< 0.001 3A3L
compared to 3A3LΔ targeted cells; $p< 0.001 3A3L or 3A3LΔ compared to early passage cells
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Fig. 3 dCas9 3A3L or dCas9 3A targeting prevents senescence and increases proliferation. a, b Proliferation was assessed using a colorimetric assay 10, 15
and 20 days after targeting dCas9 3A3L to HIC1, RASSF1, PTEN and CDKN2A and magnetic sorting in primary myoepithelial cells from donors 1, 2 and 3.
Dotted line represents the average absorbance from three dCas9 3A3LΔ targeted wells at each timepoint. The graphs show the average difference in
absorbance as fold change compared to 3A3LΔ average (mean± SEM, n= 3). c Cumulative population doublings over time for untransfected primary
myoepithelial cells and those transfected with dCas9 3A3L or 3A3LΔ targeting the four genes without magnetic sorting from donor one. Fifty thousand
cells were seeded at the start of each passage and cells counted after 5 days (mean± SEM, n= 3, where error bars are smaller than points plotted they are
not shown). (d) Light microscopy images of β-gal staining from untransfected (top left) primary myoepithelial cells from donor 1 and those transfected with
dCas9 3A3L (bottom two) or 3A3LΔ (top right) targeting the four genes without magnetic sorting 20 days after transfection, blue/green colouring shows
β-gal+ve cells; scale bar represents 125 µm. e Proliferation was assessed using a colorimetric assay 15, 20 and 25 days after targeting the four genes with
dCas9 3A3L (red), dCas9 3A (orange), dCas9 3A-C706A-3L (yellow), dCas9 3A3LΔ (green) or dCas9m4 (pale green), or targeting only dCas9 3A3L
without gRNAs (blue) without magnetic sorting using donor 1 myoepithelial cells. The data is shown as fold change compared to the average absorbance
from 3 wells without cells (mean± SEM, n= 3). f The percentage of GFP+ve cells after infection with no virus (green), hTERT with GFP marker (pink) or
GFP control (purple). At infection day 0 cells are 38 days post-transfection with dCas9 3A3L targeting the four genes (mean± SEM; n= 3, error bars are
not shown where smaller than points plotted)
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Fig. 4 DNA methylation is consistently maintained at HIC1, RASSF1 and CDKN2A. a Scatter plot of DNA methylation from all EPIC array probes comparing
donor 1 and donor 2 early passage primary myoepithelial cells (n= 1). The probes from the target genes highlighted on the plot are those that were found to
be signiﬁcantly hypermethylated at day 10 after dCas9 3A3L vs. 3A3LΔ targeting as shown in Fig. 2e. b Scatter plot of DNA methylation from all EPIC
array probes comparing donor 1 and 2 primary myoepithelial cells 38 and 37 days respectively after targeting dCas9 3A3L to HIC1, PTEN, RASSF1 and
CDKN2A. The same probes from a are highlighted (n= 1). c–f Targeted bisulﬁte sequencing at c HIC1, d PTEN, e RASSF1 and f CDKN2A. The localisation of
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shown in Fig. 4a, b
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sequencing and showed DNA methylation remained at these
regions in multiple replicate experiments using donor 1 myoe-
pithelial cells, as well as in myoepithelial cells from donors 2 and
3 (Fig. 4c–f). This also conﬁrmed our gene targets were hypo-
methylated in untransfected primary myoepithelial cells from the
three donors. Nevertheless, we noticed some variability in DNA
methylation maintenance between donors such as HIC1 and
PTEN in donor 2 compared to donor 1 and 3 (Fig. 4b, c, d). We
also found consistent hypermethylation at the C10orf41/ZNF503-
AS2 gene body in all donor myoepithelial cells transfected with
dCas9 3A3L and validated a hypomethylated region in both
control and targeted cells (Supplementary Fig. 12a and b). We
could not ﬁnd consistent hypomethylation in edited cell replicates
(Supplementary Fig. 12c, d). Gene expression analysis of the
target genes in early passage vs. dCas9 3A3L targeted (days 35–37
post-transfection) showed signiﬁcant gene repression of all tar-
geted genes (CDKN2A, RASSF1, PTEN and HIC1) in donors 1
and 3 (Supplementary Fig. 13a, b). Interestingly, for donor 2,
DNA methylation at PTEN and HIC1 was not well maintained at
late passages (Fig. 4c, d), consistent with their re-expression in
targeted cells (Supplementary Fig. 13c). Furthermore, in donor 2,
CDKN2A associated transcripts and RASSF1A were signiﬁcantly
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downregulated but other RASSF1 transcripts were not repressed
despite maintained DNA methylation at the promoter (Supple-
mentary Fig. 13c).
In summary, targeting DNA methylation via dCas9 3A3L to
the panel of genes was permanently maintained in primary
myoepithelial cells from 3 donors, albeit with some inconsistences
between donors, and this resulted in repression of all gene targets
in donors 1 and 3.
dCas9 3A3L cells activate cancer-like gene expression. To
interrogate the intracellular signalling changes that occured when
cells were prevented from entering senescence, we performed
RNA-seq using primary myoepithelial cells from donor 1, 10 days
post-transfection including pMACS magnetic sorting on day 2.
We included a third group of untransfected myoepithelial cells
(early passage cells) as a control (Supplementary Fig. 14). We
used the data to cluster samples by PCA and found that 3A3L and
3A3LΔ groups clustered together at principle component 1 (PC1;
Fig. 5a) indicating that 60% of the variance could be explained by
the time in culture. It is important to mention that as indicated by
p16 expression in Fig. 2g, some of the control 3A3LΔ cells are
already senescent at 10 days post-transfection. Gene ontology
(GO) analysis revealed both 3A3L and 3A3LΔ targeted cells had
upregulation of abnormal and cancer-associated signalling pro-
cesses compared to early passage cells (Supplementary Fig. 15a;
Supplementary Data 2); with substantial overlap between path-
ways differentially regulated in 3A3L and 3A3LΔ targeted cells
compared to the early passage group (Supplementary Fig. 15b).
Interrogating the differential gene expression between 3A3L
and 3A3LΔ targeted cells revealed a subset of transcripts (1925
genes; Supplementary Data 3) which we used to perform a second
PCA. Analysing this subset of transcripts showed that the 3A3L
targeted cells clustered more closely to the early passage cells at
PC1, accounting for 69% of the variance (Fig. 5b); this
observation was corroborated by hierarchical clustering (Supple-
mentary Fig. 16a). Expression of this subset of genes in 3A3L
more closely matches the proﬁle in early passage cells
(Supplementary Fig. 16b). This suggests that 3A3L targeting to
HIC1, RASSF1, PTEN and CDKN2A suppresses senescence and
prevents gene expression changes associated with senescence. We
used GO analysis to identify the signalling pathways associated
with the genes differentially expressed between 3A3L and 3A3LΔ
targeted cells. This identiﬁed upregulation of cell cycle- and DNA
damage-linked transcripts in DNA methylation targeted cells
(Fig. 5c). 3A3LΔ targeted cells had increased transcription
associated with aberrant processes and cancer, indicating that
the cells entering senescence had abnormal intracellular signalling
compared even to 3A3L targeted cells, although as mentioned
above both 3A3L and 3A3LΔ groups had abnormal signalling
compared to early passage (Supplementary Fig. 15).
To further elucidate the driving events behind the
observed phenotype in DNA methylation targeted cells, we used
the RNA-seq data to analyse expression of transcripts down-
stream of, or associated with p16, p14 and RASSF1A. Here we
found that the majority of these transcripts were differentially
expressed when comparing transfected cells to early passage
(Fig. 5d, e). Many associated and downstream factors from
p16 signalling were also differentially expressed between 3A3L
and 3A3LΔ targeted cells (Fig. 5d; p= 5.7 × 10−8 (Fisher’s exact
test) compared to 7 genes picked at random from total
transcripts). CDKN2B (p15), another cell cycle regulator, was
signiﬁcantly upregulated as 3A3LΔ targeted cells approached
senescence; but repressed in 3A3L targeted cells. This ﬁnding has
parallels with another study, whereby p15 was upregulated in
deeply senescent HMEC cells compared to early passage, and
expression of p15 was signiﬁcantly repressed following knock-
down of p16 by siRNA45, suggesting negative feedback regulation
of p15 after p16 repression. Surprisingly, factors downstream
from p14 such as MDM2 and p53 (TP53) were upregulated in
both 3A3L and 3A3LΔ targeted cells compared to the early
passage group (Fig. 5e); implying that p53 signalling is activated
regardless of p14 status in the cell. Similarly, transcripts
associated with RASSF1A signalling were not differentially
expressed between 3A3L and 3A3LΔ targeted cells (Supplemen-
tary Fig. 17).
In summary, this data indicates that dCas9 3A3L and 3A3LΔ
targeted myoepithelial cells had similar overall transcriptional
proﬁles by 10 days post-transfection, and this was associated with
abnormal cellular signalling. However, targeting DNA methyla-
tion to the four genes prevented cells from entering senescence by
maintaining a subset of transcript expression at levels similar to
early passage cells.
p16 epigenetic silencing prevents senescence entry. From our
RNA-seq data and substantial evidence in the
literature37, 42, 43, 46, 47, it seemed likely that the prevention of
cellular senescence we observed was driven by p16 promoter
hypermethylation and subsequent repression. To investigate this,
we targeted DNA methylation to CDKN2A, RASSF1, PTEN and
HIC1 genes individually and assessed proliferation. As predicted,
targeting all four genes or targeting the CGIs associated with
CDKN2A prevented donor 1 and 2 myoepithelial cells from
entering senescence; whereas targeting DNA methylation to
RASSF1, PTEN or HIC1 alone did not (Fig. 6a).
Next, we asked whether p16 hypermethylation was the sole
event required to drive senescence prevention in different donors.
We individually targeted each CDKN2A CGI with gRNAs
(as shown in Fig. 6b). When targeting p14 alone, only donor 1
myoepithelial cells were consistently prevented from entering
senescence (Fig. 6c) and targeting CDKN2A CGI3 had no effect
(Supplementary Fig. 18a, b). Targeting p16 alone with 3 gRNAs
was sufﬁcient to prevent senescence and enable proliferation
(Fig. 6d) comparable to cells transfected with dual p14-p16
speciﬁc gRNAs (Fig. 6e); however, as shown in Fig. 6f and
Fig. 5 RNA-seq gene expression analysis of dCas9 3A3L treated and control myoepithelial cells. a PCA analysis of RNA-seq data using all transcripts from
early passage (blue), dCas9 3A3LΔ targeted (purple) and dCas9 3A3L targeted (orange) primary myoepithelial cells from donor 1, 10 days post-
transfection targeting HIC1, RASSF1, PTEN and CDKN2A (including magnetic sorting at day 2). Each circle represents an individual biological replicate (n=
3). b PCA analysis using only data from transcripts which are differentially expressed between dCas9 3A3L and 3A3LΔ targeted cells as identiﬁed by
DESeq2 (p< 0.001; with BH correction); data are shown as early passage (blue), dCas9 3A3LΔ targeted (purple) and dCas9 3A3L targeted (orange) cells.
Each circle represents an individual biological replicate (n= 3). c GO analysis of transcripts which are differentially expressed between dCas9 3A3L and
3A3LΔ targeted cells. GO terms associated with transcripts highly expressed in dCas9 3A3L targeted cells (left panel) and 3A3LΔ targeted cells (right
panel) are shown. P value was calculated using Cytoscape (v. 3.4.0) and the add-in package Cluego (v. 2.2.5), which utilises the KEGG pathway database.
d, e Gene expression of transcripts associated with d p16 signalling and e p14 signalling from the RNA-seq data 10 days post-transfection in primary
myoepithelial cells from donor 1. Data is shown as fold change of gene expression from 3A3LΔ (purple) and 3A3L (orange) compared to average RPKM
data from early passage cells (dotted line; mean± SEM, n= 3). Signiﬁcance is from DESeq2 analysis: *p< 0.001 3A3L compared to 3A3LΔ targeted cells;
$p< 0.001 3A3L or 3A3LΔ compared to early passage
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Fig. 6 Hypermethylation and repression of p16 drives the proliferative phenotype. a Proliferation was measured using a colorimetric assay 15, 20 and
25 days after targeting dCas9 3A3L or 3A3LΔ to HIC1, RASSF1, PTEN and CDKN2A (red), CDKN2A only (orange), HIC1 only (green), RASSF1 only (blue)
or PTEN only (indigo) in donor 1 (left graph) or donor 2 (right graph) primary myoepithelial cells. Dotted lines represent the average absorbance
from three dCas9 3A3LΔ targeted wells at each timepoint. The graphs show the average difference in absorbance as fold change of 3A3L compared
to 3A3LΔ average (mean± SEM, n= 3). b Schematic showing the structure of the CDKN2A locus and the location of the gRNAs (grey boxes) in
relation to CGIs (green bar) and TSS of alternative transcripts p14 and p16. c-e Proliferation was assessed 15, 20 and 25 days after targeting dCas9
3A3L or 3A3LΔ to c p14, d p16 or e the whole CDKN2A locus in donors 1, 2 and 3 primary myoepithelial cells. Dotted lines represent average from
three dCas9 3A3LΔ targeted wells. The fold change of 3A3L compared to 3A3LΔ average is plotted (mean± SEM, n= 3). f Cumulative population
doublings for cells from donors 1, 2 and 3 transfected with dCas9 3A3L targeting p16 with gRNAs #1, #2 and #3 (orange lines) or targeting the
entire CDKN2A locus (8 gRNAs; blue lines). Fifty thousand cells were seeded at the start of each passage and cells counted after 5 days (mean± SEM,
n= 3, error bars excluded where smaller than points). g Proliferation was measured 15, 20 and 25 days after targeting dCas9 3A3L or 3A3LΔ to
CDKN2A using p14 gRNA #2/p16 gRNA #1 (magenta), p14 gRNA #3/p16 gRNA #2 (red) or p16 gRNA #1 (pink) in donor 1 myoepithelial cells.
Dotted line represents the average from three dCas9 3A3LΔ targeted wells. Data is plotted as fold change of 3A3L absorbance compared to 3A3LΔ
average (mean± SEM, n= 3)
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Supplementary Fig. 18c, dual targeting of p14-p16 resulted in
signiﬁcantly more proliferation in donor 1 and 3 respectively
compared to targeting only p16 (Supplementary Fig. 18c;
p< 0.0001; two-way ANOVA with Bonferroni post-hoc test).
Gene expression analysis 30 days post-transfection conﬁrmed
that p16 was repressed after methylation targeting to p14-p16 or
p16, whereas p14 was repressed in p14-p16-targeted cells
(Supplementary Fig. 19a–c). Expression of the functionally
related p15 transcript increased in some replicates when
methylation was targeted to p14-p16 compared to p16 alone
(Supplementary Fig. 19d), demonstrating variation in intracel-
lular processes after p14-p16 vs. p16 methylation targeting.
To exclude a contribution of dCas9 3A3L-mediated off-target
methylation to the phenotype, we used two sets of gRNAs with
different sequences and targeted CDKN2A with dCas9 3A3L
(Fig. 6g). Both combinations resulted in the primary cells
proliferating, excluding a role for off-target methylation effects
in the proliferative phenotype, as each gRNA set has different off-
targets. Notably, when we used a single gRNA targeting p16
(gRNA #1) these cells evaded senescence (Fig. 6g). This suggests
that p16 hypermethylation is sufﬁcient to prevent senescence
entry in myoepithelial cells and that targeting both p14 and p16
promoter CGIs may increase the rate of proliferation.
Finally, to extend our ﬁnding of the role of CDKN2A
hypermethylation beyond myoepithelial proliferation we targeted
hypermethylation in primary luminal cells (which line the duct
within the breast) from two donors. Using luminal cells we found
that targeting CDKN2A with dCas9 3A3L resulted in proliferation
whereas targeting dCas9 3A3LΔ did not (Supplementary Fig. 20a).
Primary luminal cells were consistently able to proliferate beyond
the expected capacity in vitro (Supplementary Fig. 20b), but also
reached a ﬁnal cell cycle arrest. Interestingly, 3A3L transfected
luminal cells were able to grow in colonies in the anchorage
independence assay (Supplementary Fig. 20c), indicating that the
luminal cells may have undergone physiological changes more
akin to transformation. Our results suggest that targeting p14-p16
hypermethylation and prevention of senescence entry is applic-
able to other primary cell types although the physiological
response might be cell dependent.
Discussion
The expanding ﬁeld of epigenome editing allows us to ask
functional questions that have hitherto been technically challen-
ging. In this study, we show that hit-and-run DNA methylation
targeting in normal primary myoepithelial cells from multiple
donors causes heritable promoter hypermethylation at CDKN2A,
RASSF1 and HIC1, with permanent repression of CDKN2A and
RASSF1 associated transcripts. This prevents a subset of gene
expression changes associated with senescence and blocks
senescence entry. Finally, we demonstrate that hypermethylation
and repression of p16 drives this phenotype and repressing the
whole CDKN2A locus increases the proliferative capacity of pri-
mary cells (Fig. 7).
Our ability to successfully target epigenetic modiﬁcations is no
longer in question9, 13–18, 48 but evidence for DNA methylation
maintenance without constitutive expression of the targeting
machinery has been limited13–16, 18, 19. In our study, repressing
CDKN2A in primary myoepithelial and luminal cells enabled
crucial anti-proliferation barriers to be overcome. Utilising the
biological context of the cell in this way separates our ﬁnding
from recent work demonstrating heritable DNA methylation
using three effector constructs16. Targeted DNA methylation was
consistently maintained at the RASSF1 locus, but this was unable
to prevent senescence entry; however repression of RASSF1A may
inﬂuence other biological processes aside from proliferation. Our
observation that RASSF1A was also repressed as cells enter
senescence may support the theory that senescence-associated
changes are not necessarily cancer-preventative and could explain
why RASSF1A hypermethylation is found at early stages of breast
neoplasms3, 26, 29. Although the PTEN and HIC1 promoters
became hypermethylated at 10 days post-transfection in donor 1,
gene expression was not affected in the bulk population. How-
ever, we did ﬁnd signiﬁcant repression after 35–37 days post-
transfection in donors 1 and 3 (Supplementary Fig. 13a, b); this
nevertheless raises the possibility that some genes can be more
resistant to DNA methylation repression.
From our EPIC array data, we found almost 1000 CpGs with
≥ 20% hypermethylation in dCas9 3A3L vs 3A3LΔ targeted cells
10 days post-transfection (0.1% of total CpG probes). These may
not be random events as there is a 70% overlap between 3A3L
replicates when the top 300 hypermethylated CpGs are analysed
(Supplementary Fig. 21, probes unmethylated in control). Cur-
rently, it is not possible for us to distinguish whether these are the
result of transient dCas9 3A3L off-target binding or whether these
are consistent biology-driven hypermethylation events occurring
after cell cycle re-entry driven by CDKN2A repression. Based on
our data showing senescence prevention using different combi-
nations of p14-p16 gRNAs, and a single p16 gRNA (Fig. 6g) we
believe that we can exclude possible dCas9 3A3L-mediated off-
target methylation from contributing to the proliferative
phenotype.
Our experiments show that the outgrowing primary myoe-
pithelial cells are not immortal and go into permanent cell cycle
arrest. A similar growth pattern has been studied extensively in
vHMECS37, 49; previous work showed that vHMEC cells (which
have escaped senescence via spontaneous p16 promoter hyper-
methylation) also eventually go into permanent cell cycle arrest
and have critically shortened telomeres and gross chromosomal
aberrations40. Our DNA methylation targeted cells in cell cycle
arrest show a similar phenotype based on increased cellular size,
cytoplasmic vacuoles and multiple nuclei and partial proliferation
rescue after the overexpression of hTERT; supporting the
hypothesis that senescence escape is the ﬁrst step in malignancy
in vivo, promoting genetic abnormalities that can destabilise the
genome and transform cells. Accordingly, several studies have
shown that p16 hypermethylation is required before
10 days after 3A3L transfection — senescence prevention
10 days after 3A3LΔ transfection — senescence
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Fig. 7 Model of epigenetic editing mediated senescence prevention. A
schematic showing the main transcriptional changes that occur 10 days
after DNA methylation is targeted to CDKN2A by dCas9 3A3L which
prevents senescence entry
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overexpression of c-MYC or hTERT can immortalise primary
HMECs36, 50.
Our work may provide foundations for understanding DNA
methylation-driven early changes in breast cancer in vivo. It is
well known that p16 is commonly misregulated in human cancer
and p16 is considered a tumour suppressor, however, the emer-
ging picture is more complex. Clearly, a lack of p16 promotes
cancer as mice models have shown that knocking out p16 (and to
a greater extent p14-p16) increases spontaneous cancer inci-
dence51; however there are additional epigenetic or genetic hits
required before disease emergence. In other studies, too much
p16 is also detrimental and increases disease risk52, including
cancer53, 54. It may be that using the levels of p16 alone is not
sufﬁcient to draw decisive and consistent conclusions about
cancer risk55, 56. Whether DNA methylation targeted to p14-p16
increases disease susceptibility is unknown, however it should be
noted that p16 promoter hypermethylation is found in histolo-
gically normal breast tissue27, 39.
Although our experiments indicate that DNA methylation
targeting is the driving modiﬁcation behind the phenotype, suc-
cessful epigenetic editing is dependent on chromatin
conformation16, 48, therefore low or repressed p16 expression
may be a prerequisite for DNA hypermethylation in primary
cells, a hypothesis that is supported by work using HMECs57.
Limitations on the number of primary cells available and the lack
of reliability for single cell histone modiﬁcation analysis makes it
difﬁcult to address this question. Interestingly, the proliferative
phenotype we observe is not restricted to primary myoepithelial
cells, it also occurs after targeting DNA methylation to CDKN2A
in primary luminal cells, suggesting a more universally relevant
biological mechanism; an important ﬁnding since it is not fully
understand whether myoepithelial cells can contribute to
luminal-type breast cancers20, 21. Exploring our observation that
targeting DNA methylation induces a more cancer-like pheno-
type in the luminal cells will be an exciting direction for future
work.
In summary, we have used dCas9 3A3L to successfully target
promoter hypermethylation in primary breast cells demonstrating
the usefulness of this construct as part of our rapidly expanding
molecular toolkit to delineate cause from consequence in diseases
such as cancer. We show that hit-and-run epigenetic editing can
be used to initiate aberrant cellular processes and we predict that
this will pave the way for identifying key epigenetic drivers in
cancer, with the potential for development of new treatments and
therapies.
Methods
Cell culture. Primary human myoepithelial and luminal cells were isolated from
reduction mammoplasty tissue as previously described58. Brieﬂy, breast tissue was
chopped into 1 cm pieces and incubated overnight with 1 mg ml−1 collagenase and
hyaluronidase in RPMI media (5% fetal bovine serum (FBS), 100 units ml−1
penicillin, 0.1 mg ml−1 streptomycin, 5ug ml−1 amphotericin B) at 37°C. Following
3x washes in medium to remove enzymes and fat, 3 × 30 min sedimentation steps
at 1g were used to separate the denser organoids from single cells such as blood
cells and ﬁbroblasts. Organoids were digested to a single cell suspension using
0.05% trypsin and 0.025% EDTA in PBS including 0.4 mg ml−1 DNase for
10–20 min at 37 °C. To isolate a pure primary myoepithelial cell population, the
single cell suspension was incubated with mouse anti-CD10 primary antibody
(#mca1556, Bio-Rad), conjugated to sheep anti-mouse immunoglobulin G Dyna-
beads at a ratio of 2:1 (cells to beads) for 30 min at 4 °C to label primary myoe-
pithelial cells. Magnetically labelled myoepithelial cells were collected using
magnetic separation and the remaining cells were incubated with Epithelial Enrich
Dynabeads for 30 min at 4 °C to label and isolate luminal cells. Healthy donors 1, 2
and 3 were aged 24, 21 and 20 respectively at time of surgery, and donor 4 (luminal
cell experiment only) was aged 28. The donor cells used for each experiment is
speciﬁed in the Figure or Figure legend. Primary myoepithelial cells were at pas-
sage 2 at the start of all experiments and were cultured on collagen coated
plates in human mammary epithelial cell medium (Thermo Fisher Scientiﬁc)
supplemented with bovine pituitary extract (50 µg ml−1; Thermo Fisher Scientiﬁc),
hydrocortisone (0.5 µg ml−1), insulin (5 µg ml−1), epidermal growth factor (EGF;
10 ng ml−1), gentamicin (10 µg ml−1) and amphotericin B (0.5 µg ml−1).
Immortalised myoepithelial cell line 1089 (created and provided by Professor
Michael O’Hare22) was generated from primary human myoepithelial cells by
mutant SV40 LT antigen (U19tsA58) and hTERT overexpression, before sorting
using integrin β4–labelled sheep anti-mouse magnetic beads to purify the myoe-
pithelial cell population23. Cells were maintained in Ham’s F12 media containing
L-glutamine, FBS (10% v/v), hydrocortisone (1 µg ml−1), insulin (5 µg ml−1) and
EGF (10 ng ml−1). Primary luminal cells were at passage 1 at the start of all
experiments and were cultured on collagen coated plates in DMEM-F-12 medium
supplemented with fetal bovine serum (10% v/v), hydrocortisone (0.5 µg ml−1),
insulin (5 µg ml−1), EGF (10 ng ml−1), apo-transferrin (10 µg ml−1), amphotericin
B (2.5 µg ml−1) and penicillin-streptomycin (100 units ml−1 penicillin, 0.1 mg ml−1
streptomycin). Cells were maintained at 37 °C in a 5% CO2 humidiﬁed incubator
and were routinely testing for absence of mycoplasma. Informed consent was
obtained from all human participants who donated their tissues to the BCI Breast
Tissue Bank.
Plasmid construction. The dCas9 3A3L fusion and dCas9 3A-C706A-3L mutant
were generated and used as previously described17 (Supplementary Fig. 1c). Brieﬂy,
the Dnmt3a–Dnmt3L single-chain construct10 was introduced to the M-SPn-Cas9-
VP64 plasmid (Addgene plasmid #48674)59 via PCR ampliﬁcation from the ZNF-
Dnmt3a3L plasmid10 and cloning using the Gibson assembly. The dCas9 3A3LΔ
plasmid contained a duplicated 100bp region within the Dnmt3l region,
rendering the construct catalytically inactive due to 3A3L mis-folding (Supple-
mentary Fig. 22). The gene promoter sequences containing CGIs from human
HIC1, RASSF1, CDKN2A and PTEN were extracted using the UCSC genome
browser60. gRNA sequences were designed using a CRISPR design tool (http://
crispr.mit.edu)61 and sequences were selected based on minimal predicted off-
target binding, with particular attention given to avoiding gRNAs with off-targets
predicted within CGIs. Sequences were selected to give good coverage of each CGI,
with 100–200 bps between each gRNA (Supplementary Table 1). The gRNA
plasmids were synthesized using complementary ssDNA oligonucleotides with
overhangs which were annealed and cloned into the empty gRNA plasmid
(Addgene plasmid #41824) using Gibson Assembly or T4 DNA ligase following the
manufacturer’s protocol, giving one plasmid per gRNA. Correct gRNA sequence in
the ﬁnal plasmid construct was conﬁrmed by Sanger sequencing.
Transfections. For 1089 transfection, cells were seeded 8.5 × 105 cells in a T75
ﬂask and transfected the following day using 12.7 ug total plasmid, (35% Cas9
3A3L or 3A3LΔ, 41% equimolar pooled HIC1 gRNAs (8.2% per gRNA) and 24%
magnetic activated cell sorting (MACS) plasmid Kk.II (pMACS; MACSelect sys-
tem; Miltenyi Biotech); jetPrime (Polyplus) ratio 1:2.6), magnetic sorting resulted
in at least 80% transfected cells. For experiments using primary myoepithelial cells,
6 well plates were collagen coated before seeding 2 × 104 cells well−1. After 3 days,
primary cells were pre-treated for 4 h with hyaluronidase (3mg ml−1) to increase
transfection efﬁciency before cells were washed in phosphate buffered saline (PBS)
and incubated with the transfection cocktail for 4 h. The proportions of dCas9
3A3L or 3A3LΔ, gRNAs and pMACS were adjusted depending on the number of
gRNAs. We transfected plasmid quantities based on total pmol (0.45 pmol total per
well; jetPrime ratio 1:9.67) due to the difference in size between the dCas9 plasmids
and gRNAs. The plasmid cocktails were as follows: for 26 gRNAs: 0.037 pmol
dCas9 3A3L or 3A3LΔ, 0.374 pmol gRNAs (0.0144 pmol per gRNA), and 0.038
pmol pMACS; for 5 gRNAs (targeting HIC1 or PTEN): 0.1 pmol dCas9 3A3L or
3A3LΔ, 0.25 pmol gRNAs (0.05 pmol per gRNA), and 0.1 pmol pMACS. For 8
gRNAs (targeting RASSF1 or all CDKN2A locus): 0.077 pmol dCas9 3A3L or
3A3LΔ, 0.296 pmol gRNAs (0.037 pmol per gRNA), and 0.077 pmol pMACS. For
targeting the p14 CGI (4 gRNAs): 0.11 pmol dCas9 3A3L or 3A3LΔ, 0.225 pmol
gRNAs (0.056 pmol per gRNA), and 0.11 pmol pMACS. For targeting the p16 CGI
(3 gRNAs): 0.11 pmol dCas9 3A3L or 3A3LΔ, 0.226 pmol gRNAs (0.067 pmol per
gRNA), and 0.11 pmol pMACS. For CDKN2A CGI3 targeting (1 gRNAs): 0.17
pmol dCas9 3A3L or 3A3LΔ, 0.11 pmol gRNA, 0.17 pmol pMACS. Magnetic
enrichment was performed 2 days after transfection for some experiments and this
is stated in the Figure legends, giving at least 80% transfection efﬁciency. For
experiments which did not involve magnetic sorting the same total amount of
pmols was transfected as above without the pMACS and the amount of other
plasmids was increased proportionally, this gave 20–25% transfection efﬁciency.
For the combination targeting shown in Fig. 6g we used p14 gRNA #2 and p16
gRNA #1 or p14 gRNA #3 and p16 gRNA #2 (2 gRNAs): 0.225 pmol dCas9 3A3L
or 3A3LΔ, 0.225 pmol gRNAs (0.1125 pmol per gRNA). For p16 targeting using
only a single gRNA shown in Fig. 6g, we used p16 gRNA #1: 0.26 pmol dCas9
3A3L or 3A3LΔ, 0.19 pmol gRNA #1. For the multiple Cas9 targeting experiment
shown in Fig. 3e we used 0.413 pmol of gRNAs (all 26x gRNAs, 0.016 pmol per
gRNA) and 0.037 pmol of dCas9 3A3L, 3A3LΔ, 3A, 3A-C706A-3L or the Cas9
quadruple mutant (dCas9m4) with 0.413 pmol of gRNA. We used 0.45 pmol of
dCas9 3A3L for transfection without gRNAs. For experiments using primary
luminal cells the transfection procedure was the same but with a total of 0.8 pmol
of plasmid and 1:7 of pmol:jetPrime reagent as these cells are more challenging to
transfect.
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Bisulﬁte cloning. Genomic DNA was extracted (PureLink; Thermo Fisher Sci-
entiﬁc) before bisulﬁte conversion (Imprint, Sigma-Aldrich) following manu-
facturer’s guidelines. Regions within HIC1 or RASSF1 gene promoters were
ampliﬁed using bisulﬁte-speciﬁc primers (Supplementary Table 2). Puriﬁed
bisulﬁte-treated DNA was added to a mastermix (1x reaction buffer, 2 mM MgCl2,
0.025 units µl−1 HotStarTaq (Qiagen), 200 µM of each deoxynucleoside tripho-
sphate (dNTP), 0.20 μM forward and reverse primers) and ampliﬁed using a
thermocycler. PCR products were puriﬁed and sub-cloned using p-GEMT (Pro-
mega) and 5-alpha competent E. coli, before single positive colonies were picked
and sequenced using Sanger sequencing and vector speciﬁc primers.
Global DNA methylation analysis. The Illumina Inﬁnium HumanMethylatio-
nEPIC (EPIC) array was used to analyse global DNA methylation differences.
Primary myoepithelial cells from donor 1 were seeded and transfected 3 days later
with dCas9 3A3L or 3A3LΔ, all 26 gRNAs and pMACS as described. Each replicate
(n= 3) was performed as an entirely separate transfection experiment. Successfully
transfected cells were magnetically sorted 2 days post-transfection and replated.
10 days post-transfection cells were harvested and either genomic DNA or RNA
(see below RNA-seq) was extracted. Since the EPIC array requires at least 250ng of
genomic DNA and there are limitations on the number of primary cells for each
experiment and low transfection efﬁciencies, genomic DNA for dCas9 3A3LΔ
targeted replicates 2 and 3 were pooled (these are replicates 2 and 3 in the RNA-seq
analysis i.e. not pooled for the RNA-seq experiment). Another separate transfection
of dCas9 3A3LΔ and gRNAs was used as replicate 3 in the EPIC array. Data shown
in Fig. 4a are from early passage myoepithelial cells (i.e. passage 2 cells grown for
3 days before harvesting) from donors 1 and 2 (n= 1). Data shown in Fig. 4b are
from myoepithelial cells from donor 1 and 2 transfected with dCas9 3A3L, all 26
gRNAs and pMACS before magnetic enrichment and culturing for 38 days (donor
1) or 37 days (donor 2) (n= 1). DNA (400–500 ng) was bisulﬁte converted and
DNA methylation was quantiﬁed using the EPIC BeadChIP (Illumina) run on an
Illumina iScan System using the manufacturer’s standard protocol. Raw IDAT ﬁles
were processed using the ChAMP package (v. 2.8.2) in R using BMIQ normal-
isation62 to generate methylation β-values and calculate signiﬁcant DMRs. All
downstream analysis was conducted using the hg19/GRCh37 human genome
assembly. Annotation of DMRs and signiﬁcant overlap at genomic features was
calculated using regioneR (v. 1.8.0). PCA analysis was performed using DNA
methylation data from all probes.
Targeted bisulﬁte sequencing. Passage 2 primary myoepithelial cells from donor
1, 2 and 3 were seeded and either cultured for 3 days before harvesting (early
passage) or they were transfected after 3 days with dCas9 3A3L, all 26 gRNAs and
pMACS. Transfected cells were magnetically sorted after 2 days and then cultured
until 35–41 days post-transfection with regular passaging before harvesting cells
and extracting genomic DNA. DNA was bisulﬁte converted and ampliﬁed by PCR
using primers speciﬁc to target regions (Supplementary Table 2). PCR products
were puriﬁed using SPRI beads (Agencourt AMPure XP, Beckman Coulter).
Amplicons were end repaired and A-tailed (Agilent Technologies) before ligation
to unique TruSeq HT double indexed adapters. Samples were pooled and PCR
ampliﬁed with 8 cycles using Illumina speciﬁc primers and quantiﬁed with the
NEBNext Library quantiﬁcation kit for Illumina (New England Biolabs). Sequen-
cing was performed on an Illumina MiSeq with 150bp paired-end reads at Barts
and the London Genome Centre (London, UK). Reads were quality trimmed with
Trim Galore (v. 0.4.1) and mapped to the human genome using Bismark (v.0.14.4)
before visualization and quantiﬁcation using SeqMonk (v. 0.34.1).
Proliferation assay. For measuring proliferation in experiments which involved
magnetic sorting (Fig. 3a, b, Supplementary Fig. 6a) on day 2 after transfection and
immediately after magnetic sorting, primary myoepithelial cells were seeded in
triplicate at 780 cells cm−1 (± 10%). Proliferation was assessed on days 10, 15 and
20 after transfection using different wells for each timepoint and using CellTiter-
Blue (Promega) by diluting reagent 1:5 with media and incubating for 1–4 h.
Proliferation was quantiﬁed by measuring the absorbance at 550nm and 620nm as
a reference and data were normalised to the average absorbance of 3 wells without
cells. For seeding density experiments (Supplementary Fig. 6), cells were magne-
tically sorted 2 days post-transfection and cultured until 10 days post-transfection
before reseeded in a 96 well plate at 3120 cells cm−1 (± 10%; high density),
1560 cells cm−1 ( ± 10%; medium density), 780 cells cm−1 (± 10%; low density).
Proliferation was quantiﬁed at 15 and 20 days after transfection. For experiments
which did not involve magnetic sorting (a change in method to reduce cell death
and increase the number of conditions possible for each experiment), we trans-
fected primary myoepithelial cells as described and then cultured cells until 10 days
post-transfection before reseeding cells in triplicate at 780 cells cm−1 ( ± 10%) in a
96 well plate. Proliferation was assessed at days 15, 20 and 25 after transfection
using CellTiter-Blue as described. For luminal data, cells were seeded and after
3 days were transfected with dCas9 3A3L or 3A3LΔ and all 26 gRNAs as described.
After 15 days cells were reseeded in a 96 well plate in triplicate and proliferation
assessed at 20, 25 and 30 days after transfection.
Population doublings. Population doublings were calculated over multiple pas-
sages by seeding 50,000 cells at the start of each passage and counting the number
of cells at the end of the passage (i.e. 5 days later for primary myoepithelial cell
experiments). Doublings were calculated using the formula:
log2
no: of cells at end of passage
no: of cells at start of passage
Data are plotted as the cumulative population doubling over time. Negative or
decreasing cumulative population doublings occur when fewer cells were present at
the end of the passage than at the start (i.e. when cells are not growing).
Β-galactosidase (β-gal) staining. Primary myoepithelial cells were seeded and
either cultured as an untransfected control or transfected with dCas9 3A3L or
dCas9 3A3LΔ with 26 gRNAs. Cells were cultured for 20 days and then ﬁxed in
culture plates for overnight β-gal staining using a kit (New England Biolabs) fol-
lowing the manufacturer’s instructions. Images of the staining were taken using a
light microscope.
hTERT overexpression. The Platinum-A (Plat-A) amphotropic retroviral packa-
ging cell line (Cell Biolabs) was maintained in DMEM containing 4.5 mg ml−1
glucose, L-glutamine, 10% v/v FBS, 10 µg ml−1 blasticidin and 1 µg ml−1 pur-
omycin. A retroviral vector expressing hTERT with a GFP marker (Addgene
#69809) and a GFP-only control vector (Addgene #21654) were transfected into
the Plat-A cells using jetprime. Fresh media without selection antibiotics was put
on Plat-A cells 24 h after transfection. Virus-containing supernatant was removed
24 h later, ﬁltered and mixed in a 1:1 ratio with primary myoepithelial media before
adding to primary cells. 7 days after infection and every 5 days subsequently, cells
were passaged and the total number counted. Fifty-thousand cells were reseeded
after each passage and the cumulative population calculated as described. The
remaining cells at each passage were stained with 4’,6-diamidino-2-phenylindole
(DAPI) to exclude dead cells and the percentage of GFP+ve cells was assessed for
both hTERT and control infected cells using LSR Fortessa (BD Biosciences) fol-
lowing the manufacturer’s instructions.
RNA-sequencing (RNA-seq). Each replicate (n= 3) was performed using donor 1
myoepithelial cells but as an entirely separate transfection experiment performed
on different days. For RNA-sequencing, primary myoepithelial cells at passage 2
were seeded and after 3 days, early passage cells were harvested. On the day of early
passage harvesting, the remaining cells were transfected with dCas9 3A3L or dCas9
3A3LΔ, all 26 gRNAs and MACS plasmid as described. Cells were magnetically
sorted 2 days post-transfection and then cultured until 10 days post-transfection at
which point they were harvested. As described in the ‘Global methylation analysis’
section, dCas9 3A3L or 3A3LΔ targeted cells from this experiment were also used
for DNA methylation analysis on the EPIC array. For RNA-seq, total RNA was
extracted using Direct-zol (Zymo Research) and DNase treated (Thermo Fisher
Scientiﬁc), before mRNA was isolated from 1.5 µg of total RNA using mRNA
DIRECT (Thermo Fisher Scientiﬁc) and fragmented with RNA fragmentation
reagent. First strand cDNA synthesis was performed with SuperScript III First-
Strand Synthesis System and 3 μg μl−1 random hexamers (Thermo Fisher Scien-
tiﬁc) followed by second strand synthesis with DNA polymerase I and RNase H.
After puriﬁcation using SPRI beads, the double stranded cDNA was ligated to in
house designed adapters (based on TruSeq Indexed adapters (Illumina)) using
NEBNext Ultra II (NEB) followed by 15 cycles of ampliﬁcation and library pur-
iﬁcation. Sequencing was performed on an Illumina HiSeq4000 with 75bp paired-
end at the Oxford Genomics Centre (The Wellcome Trust Centre for Human
Genetics, Oxford, UK). Genomic mapping of short reads was performed by the
Oxford Genomics Centre using bwa (v. 0.7.0) to the human genome (GRCh37).
RNA-sequencing analysis was performed using SeqMonk and the inbuilt RNA-seq
quantitation pipeline which automatically corrects for the total number of reads.
The R package DESeq2 was used to calculate differentially expressed transcripts
between groups (p< 0.001 with Benjamin Hochberg multiple test correction). PCA
analysis was performed using either all transcripts or the subset of transcripts
signiﬁcantly differentially expressed between 3A3L and 3A3LΔ targeted cells. PCA
plots were calculated by exporting the raw counts from SeqMonk before rlog
transforming and using the PCA plotting function in DESeq2. For GO analysis, we
used Cytoscape (v. 3.4.0) and the add-in package Cluego (v. 2.2.5), which utilises
the KEGG pathway database. Hierarchical clustering and violin plots were created
using SeqMonk.
Gene expression analysis. For target gene expression analysis using qPCR, RNA
was extracted from samples as above and DNase treated before cDNA conversion.
cDNA was mixed with a SYBR Green mastermix before qPCR to assess gene
expression. Gene expression was normalised to a single housekeeping gene, either
ACTB or GAPDH, to save material and primers were designed using Primer3plus
(Supplementary Table 3). Data was analysed using the Pffafﬂ method63.
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IncuCyte analysis of cell density effect on growth. For IncuCyte analysis of
growth with different seeding density (Supplementary Fig. 6b-d), cells were mag-
netically sorted 2 days post-transfection and cultured until 10 days post-
transfection before reseeded in a 96 well plate at 3120 cells cm−1 (± 10%; high
density), 1560 cells cm−1 ( ± 10%; medium density), 780 cells cm−1 (± 10%; low
density). Cells were cultured in an incubator connected to an IncuCyte Live Cell
Analysis System. At 10x magniﬁcation, 1 image hour−1 of three locations per well
were taken over 13 days and the conﬂuency of the cells was calculated by creating
an image collection and processing deﬁnition using the IncuCyte ZOOM con-
ﬂuence processing software.
Anchorage independent growth. Primary myoepithelial or luminal cells were
seeded 600 cells per 24 well plate in a 300 µl mixture of 50% complete culture
media and 50% Matrigel Matrix (Corning). After 1 h in the incubator 300 µl of
media was carefully layered on top; media was changed weekly and images were
taken 12–14 days post-seeding as described in Figure legend.
Flow cytometry for dCas9 3A3L or 3A3LΔ. The myoepithelial 1089 cell line was
trypsinised and ﬁxed in 4% paraformaldehyde for 20 min at 4°C. After washing in
staining buffer (3% v/v FBS, 0.02% w/v sodium azide in PBS), cells were per-
meabilised in 88% v/v methanol at −20°C for 10 min before a further wash in
staining buffer. Mouse anti-Cas9 antibody (1:1000; Active Motif #61577) was
added and cells were incubated for 30 min at room temperature. After washing,
cells were incubated with anti-mouse 2° Alexa 647 (1:500; Thermo Fisher Scientiﬁc
#A21235) for 30 min at room temperature. Flow cytometry was performed using
LSR Fortessa following the manufacturer’s instructions.
Immunostaining. For immunocytochemistry, primary myoepithelial cells were
grown in 24 well plates before ﬁxing in 10% neutral buffered formalin for 10 min.
Wells were pre-treated with hydrogen peroxide (100 µl H2O2 30% w/v in 10ml
PBS) to reduce endogenous peroxidase activity. Cells were permeabilised (0.1%
Triton X-100, PBS, 15 min), before blocking (5% bovine serum albumin (BSA),
15% normal goat serum, PBS, 1 h). Cells were incubated with 1 µg ml−1 1° mouse
antibodies (anti-CK14 (#PA0074 Leica Biosystems); anti-Ki-67 (clone MIB-1 Ali-
gent Technologies); anti-CK8 (clone 2E4 Sigma-Aldrich) or anti-IgG (#A9044
Sigma-Aldrich)) in blocking buffer for 1 h. After washing, 2° antibody was added
(1:1000; biotin conjugated goat anti-mouse (Sigma-Aldrich)) for 1 h before incu-
bating with Vectastain ABC kit (1 h; Vector Laboratories) and developing with
DAB (3,3’-diaminobenzidine tetrahydrochloride; (Vector Laboratories)). For
immunoﬂuorescence, 1089 cells were attached to slides using a cytospin, before
ﬁxing with 4% w/v paraformaldehyde in 1 mM PBS. Cells were permeabilised using
0.2% Triton X-100 before adding anti-Cas9 (1:200, mouse; Active Motif #61577)
for 1 h. After adding 2° antibody Alexa 388 anti-mouse (1:200, Life Technologies
#A11001), slides were dried and coated in vectorshield mounting media containing
DAPI (Vector Laboratories) and visualised using Eclipse Ci (Nikon) ﬂuorescent
microscope.
Statistical analysis. Signiﬁcance testing was performed using Prism (v.5.04) and
Student’s T-test, one-way ANOVA or two-way ANOVA with Bonferroni post-hoc
tests as speciﬁed in the Figure legends. All experiments were repeated at least three
times, unless stated otherwise. Where applicable, data are plotted as mean± SEM.
Data availability. RNA-seq and EPIC array data that support the ﬁndings of this
study have been deposited in Gene Expression Omnibus (GEO) the accession code
GSE100209 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100209).
All other data that support the ﬁndings of this study are available from the cor-
responding authors upon reasonable request.
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